Unilife whistleblower case blows over; Ex-exec apologises

By Gareth Macdonald contact

- Last updated on GMT

Unilife whistleblower retracts allegations
Unilife whistleblower retracts allegations

Related tags: Food and drug administration

An erstwhile whistleblower who accused Unilife of fraud and violating US FDA validation regulations has apologised and withdrawn his allegations.

Former Unilife employee Talbot Smith retracted claims​ he was unfairly dismissed in 2012 “because of his opposition to and protected disclosures relating to shareholder fraud and Unilife’s failure to comply with the requirements of the Food and Drug Administration.”

But in a statement issued last night Mr Smith said: “I would like to correct issues arising from claims I brought against Unilife. I now understand that there were no violations of FDA regulations during my tenure at Unilife​.”

In addition, in the summer of 2011, Unilife issued press releases which stated that they had begun shipments of validated Unifill product to customers. I now understand that the production process was in fact validated​.”

The statement brings to an end years of legal wrangling and counterclaims, including an allegation that Smith had illegally recorded a conversation​ with Unilife COO Ramin Mojdeh in 2012.

Unilife lawyer John Ryan said the firm’s rejection of the allegations had been vindicated and added that Smith had not been paid to settle the case.

"We are also pleased that in addition to apologizing to Unilife, Mr. Smith agreed to make a payment to the Company to settle our claims against him, that he received no payment as part of the resolution and dismissal, and that his attorney received only a small portion of her fees from our insurer.  With this case now behind us, we look forward to focusing our resources fully on the growth of our business.​"

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Related suppliers

Follow us

Products

View more

Webinars